Business Analytics Specialist

Crown NL Bidco B.V. has announced a voluntary public takeover offer for all issued ordinary shares of Qiagen N.V. The offer price is €46.50 per share, formalised on October 21, 2026. Crown NL Bidco is a holding company indirectly controlled by the EQT XI fund. Co-investors include subsidiaries of the Abu Dhabi Investment Authority and the Canada Pension Plan Investment Board. The two parties reached a business combination agreement. Qiagen's management and supervisory boards support the offer and recommend it to shareholders. Completion depends on a minimum acceptance threshold, merger clearances, and other conditions. The offer documentation is expected in mid-2027, and an extraordinary general meeting will approve corporate measures and post-closing steps.

QIAGEN brings Global Tuberculosis specialists together as funding pressures test TB progress. The Global TB Clinical and Educational Summit runs from 13 to 16 October, combining online sessions with an on-site meeting in London as experts address prevention, screening, care and the impact of funding cuts. QIAGEN supports tuberculosis control through education and diagnostic testing, including blood-based testing used to detect TB infection. QIAGEN N.V. is convening tuberculosis specialists from around the world for its Global TB Clinical and Educational Summit from 13 to 16 October 2026, as persistent disease burden and growing pressure on global health funding challenge progress against TB. The company said the Summit will focus on prevention, screening and care, while also highlighting the role of education and diagnostic testing, including its QuantiFERON-TB Gold Plus blood-based assay. The programme includes online sessions from 13 to 15 October and online and on-site participation at the Royal College of Physicians in London on 16 October. (PRESS RELEASE) VENLO, Netherlands, 14-Oct-2026 - /EuropaWire/ - QIAGEN N.V. will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from 13 to 16 October 2026, as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis prevention, screening and care. According to the World Health Organization's Global Tuberculosis Report 2025, an estimated 10.7 million people worldwide developed tuberculosis in 2024 and nearly 1.2 million died from the disease. While global TB deaths have declined, the number of people developing the disease remains persistently high, highlighting the need to sustain prevention, detection and treatment efforts. The Summit comes as cuts to international health funding place TB programmes under increasing strain. QIAGEN said the World Health Organization has warned that reductions in donor funding threaten essential TB prevention as well as diagnostic and treatment services. A key discussion on 15 October, "TB at risk - the global consequences of funding cuts and the future of tuberculosis control," will bring together experts from academia, clinical practice, advocacy and international TB organisations. "The world has made progress against tuberculosis, but that progress cannot be taken for granted," said Dr. Christine Ginocchio, Chief Medical Officer at QIAGEN. "Millions of people still develop TB every year, and pressure on funding and public health systems could slow further advances. Bringing experts together, strengthening education and identifying people with TB infection are practical ways we can help sustain momentum toward better prevention and care." QIAGEN supports TB control through both education and diagnostic testing. Its activities include the annual Global TB Clinical and Educational Summit and QuantiFERON-TB Gold Plus (QFT-Plus), a blood-based interferon-gamma release assay used to detect TB infection and TB disease. QFT-Plus can be used to detect TB infection as an aid to identify people who may benefit from preventive treatment, particularly those at increased risk for TB disease. More than 160 million QuantiFERON-TB tests have been sold worldwide since launch, with customers in more than 130 countries and more than 2,700 peer-reviewed publications involving QuantiFERON. For more than a decade, the Global TB Clinical and Educational Summit has brought together clinicians, laboratory professionals, researchers, nurses, advocates, survivors and public health leaders to exchange knowledge and experience in TB detection, treatment, prevention and patient care. The 2026 Global TB Summit, under the theme "One world, one fight: Let's end TB together," will take place online from 13 to 15 October and online and on-site at the Royal College of Physicians in London on 16 October. Discussions will focus on major challenges facing TB control, including prevention and screening, drug-resistant and childhood TB, vulnerable populations and access to care. Sessions will also examine the role of interferon-gamma release assays in screening people at increased risk of developing TB disease, including patients receiving kidney dialysis or biologic therapy, immunocompromised patients and older adults. The Summit is free to attend and offers CME- and CPD-accredited learning. Further information on the programme and registration is available at QIAGEN's TB Summit page. About QIAGEN. QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit http://www.qiagen.com. Forward-Looking statement. Certain statements in this press release may constitute forward-looking statements within the meaning of the U.S. federal securities laws. These statements include, among others, statements regarding QIAGEN's products, product development and launches, regulatory approvals, market opportunities and future business performance. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the development and commercial success of new products, regulatory approvals, competition, changes in customer demand and funding, economic and market conditions, supply chain disruptions, cybersecurity incidents, litigation and other risks described under "Risk Factors" in QIAGEN's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. QIAGEN undertakes no obligation to update any forward-looking statement except as required by law. Investor Relations contacts. Daniel Wendorff Vice President, Head of Investor Relations Mobile: +49 152 01811322 [email protected] Dr. Domenica Martorana Associate Director Global Investor Relations Mobile: +49 152 018 11244 [email protected] Alexandra Koenig Investor Relations Coordinator Mobile: +49 152 018 11709 [email protected] Press contacts. John Gilardi Vice President, Head of Corporate Communications, Global Germany: +49 2103 29 11711 Mobile: +49 152 018 11711 [email protected] Lisa Specht Manager Public Relations, Corporate Communications Germany: +49-2103-29-14181 Mobile: +49-152-018-11381 [email protected] Jana Radoi Corporate Communications Coordinator, Global Mobile: +49 152 018 11670 [email protected] Heeyoung Lee Asia-Pacific region topics South Korea: +82 226265788 Mobile: +82 01093389650 [email protected] Natalia Silo Latin America region topics Mobile: +55 11 98702 0137 [email protected]

QIAGEN convenes global tuberculosis experts as new pressures challenge progress against tuberculosis. Key Takeaway: QIAGEN N.V. is hosting the Global TB Clinical and Educational Summit from October 13-16, gathering tuberculosis experts to address the ongoing challenges posed by the disease. With an estimated 10.7 million new cases and nearly 1.2 million deaths in 2024, the summit aims to enhance focus on prevention, screening, and care amidst increasing pressures on global health funding. Market sentiment analysis. Positive factors. * Global experts are convening to address tuberculosis challenges. * Focus on prevention, screening, and care is being renewed. * The summit aims to tackle the persistent disease burden. VENLO, Netherlands & GERMANTOWN, Md.-(BUSINESS WIRE)- $QGEN #QIAGEN-QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis prevention, screening and care. An estimated 10.7 million people worldwide developed tuberculosis in 2024 and nearly 1.2 million died from the d Frequently asked questions. When is the Global TB Summit hosted by QIAGEN? The Global TB Clinical and Educational Summit is from October 13-16. What is the focus of the QIAGEN TB Summit? The summit focuses on tuberculosis prevention, screening, and care. How many people developed tuberculosis in 2024? An estimated 10.7 million people developed tuberculosis in 2024. What are the current pressures on tuberculosis progress? Growing pressures on global health funding challenge progress against tuberculosis.